

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A transgenic non-human mammal ~~carrying~~ comprising a mouse GANP gene or a human GANP gene transferred thereto or [[its]] progeny thereof, wherein said transgenic non-human mammal expresses GANP.

2. (Currently Amended) The transgenic non-human mammal according to claim 1, wherein the ~~transferred~~ GANP gene is expressed in B cells of the transgenic non-human mammal, or its progeny.

3. (Previously Presented) The transgenic non-human mammal according to claim 1 or 2 wherein the mammal has been generated from GANP gene-transfected ES cells, or its progeny.

4. (Cancelled)

5. (Currently Amended) A part of ~~[[the]] a~~ transgenic non-human mammal ~~according to claim 1 or its progeny~~ comprising a mouse GANP gene or a human GANP gene, or progeny thereof, wherein said transgenic non-human mammal expresses GANP.

6. (Currently amended) A method of producing a high affinity antibody, comprising:
administering an antigen to the transgenic non-human mammal according to claim 1 or its progeny;

waiting for a time sufficient for said non-human mammal to generate antibodies to said antigen; and

recovering the antibody from the resultant mammal or progeny.

7-11. (Cancelled)

12. (Currently Amended) A high affinity-antibody producing cell which is taken from ~~[[the]]~~ a transgenic non-human mammal according to claim 1 or its progeny comprising a mouse GANP gene or a human GANP gene, or progeny thereof, wherein said transgenic non-human mammal expresses GANP, and wherein said transgenic mammal or its progeny has been administered an antigen.

13. (New) The method according to claim 6, comprising:
obtaining blood from the mouse after administration of the antigen,
separating and purifying antibodies from the blood to recover the antibody.

14. (New) The method according to claim 6, wherein the antigen is administered two to three times at intervals of from 7 to 30 days.

15. (New) The method according to claim 6, wherein an administration does of the antigen is from 0.05 mg to 2 mg.

16. (New) The method according to claim 6, wherein the route of administration is subcutaneous, dermal, intraperitoneal, intravenous or intramuscular.

17. (New) The transgenic non-human mammal according to claim 1, wherein said GANP gene is operably limited to a human IgG enhancer, or its progeny.

18. (New) The method according to claim 6, wherein said GNAP gene is operably limited to a human IgG enhancer.

19. (New) The cell according to claim 12, wherein said GANP gene is operably limited to a human IgG enhancer, or its progeny.